Ultragenyx Pharmaceutical Inc. (RARE) — 10-Q Filings

10-Q Filings (6)

• Ultragenyx Losses Widen on Soaring R&D, Revenue Growth Continues — Nov 5, 2025 Risk: high
  Ultragenyx Pharmaceutical Inc. (RARE) reported a net loss of $180.4 million for the three months ended September 30, 2025, a significant increase from the $133.
• Ultragenyx Narrows Q2 Loss on Strong Product Sales Growth — Aug 6, 2025 Risk: medium
  Ultragenyx Pharmaceutical Inc. reported total revenue of $120.3 million for the three months ended June 30, 2025, a significant increase from $98.7 million in t
• Ultragenyx Pharmaceutical Inc. Files Q1 2025 10-Q — May 7, 2025 Risk: medium
  Ultragenyx Pharmaceutical Inc. filed its 10-Q for the period ending March 31, 2025. The filing details financial performance and operational updates for the fir
• Ultragenyx Pharmaceutical Inc. Files Q3 2024 10-Q Report — Nov 6, 2024 Risk: medium
  Ultragenyx Pharmaceutical Inc. filed its 10-Q for the period ending September 30, 2024. The company reported on its financial performance and business operation
• Ultragenyx Pharmaceutical Inc. Files Q2 2024 10-Q — Aug 2, 2024 Risk: medium
  Ultragenyx Pharmaceutical Inc. filed its 10-Q for the period ending June 30, 2024. The company reported on its financial position and operational activities. Ke
• Ultragenyx Pharmaceutical Inc. Files 10-Q for Period Ending March 31, 2024 — May 3, 2024 Risk: medium
  Ultragenyx Pharmaceutical Inc. (RARE) filed a Quarterly Report (10-Q) with the SEC on May 3, 2024. Ultragenyx Pharmaceutical Inc. filed a 10-Q report for the pe

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX